Bone Biologics arrived at the second quarter as it has arrived at every quarter for the past decade: with no revenue, no product, and a clinical-stage thesis that lives or dies on a single protein. Q2 was a quiet quarter on that front. Net loss was $773,702, essentially flat to the year-ago $740,519, on operating expenses of $808,106 that rose 8.0% year over year as research-and-development spend rebounded by 61.1% to $308,747 - work on extending the shelf life of the company's lead recombinant human protein, NELL-1. The load-bearing number for this quarter is not the loss; it is what the loss bought. Two days after the quarter closed, on August 12, management reported that the validated shelf life of rhNELL-1 had been extended to 32 months, up from 24 months at year-end 2025 and 29 months in May. For a single-dose biological that has to sit in a hospital pharmacy for two-plus years before a surgeon reconstitutes it at the bedside, the shelf life is the manufacturing readiness milestone that gates the eventual PMA submission. The open question is whether the rest of the runway gets the program there: the cash balance of $4.0 million at quarter-end, the $2.7 million net raised on July 9 in a private placement, the 945,677 pre-funded warrants already exercised, and a $35 million mixed-shelf taken effective in late July give the company visibility into the second quarter of 2027 - but the same shelf also opens a dilution overhang against a $0.65 stock that, at the August 14 close, leaves the entire market capitalization of the enterprise at roughly $1.8 million.